Mylan Recalls Loxapine Capsules Due to Manufacturing Deviations
Mylan Pharmaceuticals is voluntarily recalling 11,650 bottles of Loxapine Capsules 50 mg due to Current Good Manufacturing Practice (CGMP) deviations.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The recall is classified as FDA Class II, which typically corresponds to a High severity score (3) as it involves a risk of temporary or medically reversible adverse health consequences, without reported fatalities or serious injuries that would elevate it to Critical or Severe.
Plain-English summary
Mylan Pharmaceuticals Inc. is voluntarily recalling 11,650 bottles of Loxapine Capsules, USP 50 mg, Rx Only, 100-count bottles (NDC 0378-7050-01). The recall was initiated on April 24, 2018, due to Current Good Manufacturing Practice (CGMP) deviations. The affected lots are 3079386, 3079387, 3079388 (Exp. 10/31/18) and 3083762, 3083763, 3083764, 3083765, 3083766, 3083767 (Exp. 3/31/19).
The product was distributed throughout the United States, including Puerto Rico. The FDA classified this recall as Class II, which indicates that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Consumers and healthcare providers should stop using the affected product and contact their healthcare provider or pharmacist for guidance. The recall was terminated on August 14, 2019.
The recalled product
- Product
- Loxapine Capsules, USP 50 mg, Rx Only, 100-count bottles, NDC 0378-7050-01
- Manufacturer
- Mylan Pharmaceuticals Inc.
- Category
- Drug — Antipsychotic
- Hazard
- Affected units
- 11,650
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (10)
- NDC 0378-7050-01 Lot Numbers: 3079386
- Exp. 10/31/18 3079387
- Exp. 10/31/18 3079388
- Exp. 10/31/18 3083762
- Exp. 3/31/19 3083763
- Exp. 3/31/19 3083764
- Exp. 3/31/19 3083765
- Exp. 3/31/19 3083766
- Exp. 3/31/19 3083767
- Exp. 3/31/19
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 2 recalled by Mylan Pharmaceuticals Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Mylan Pharmaceuticals Inc.
See all →- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- HighMycophenolate Mofetil Injection Recalled Due to Precipitate in Vials
FDA (Drugs) · 2026-08-05
- HighAmnesteem isotretinoin 40 mg capsules failed dissolution specifications
FDA (Drugs) · 2026-03-11
- HighPrasugrel 5 mg Tablets Recalled Due to Failed Dissolution Specifications
FDA (Drugs) · 2025-03-26
- CriticalInsulin Glargine Prefilled Pens Recalled for Missing Label
FDA (Drugs) · 2022-08-03
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- SevereShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19